Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma Group (MREO) EBIT Margin: 2023-2025

Historic EBIT Margin for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -3,681.99%.

  • Mereo BioPharma Group's EBIT Margin fell 633723.00% to -3,681.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 15,306.51%, marking a year-over-year increase of 66888985.00%. This contributed to the annual value of 3,457.23% for FY2024, which is 374139.00% up from last year.
  • As of Q3 2025, Mereo BioPharma Group's EBIT Margin stood at -3,681.99%, which was down 108.42% from 43,745.83% recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's EBIT Margin ranged from a high of 43,745.83% in Q2 2025 and a low of -3,681.99% during Q3 2025.
  • Moreover, its 3-year median value for EBIT Margin was 2,655.24% (2024), whereas its average is 5,643.67%.
  • Data for Mereo BioPharma Group's EBIT Margin shows a peak YoY increase of 3,987,453bps (in 2025) and a maximum YoY decrease of 633,723bps (in 2025) over the last 5 years.
  • Mereo BioPharma Group's EBIT Margin (Quarterly) stood at -712.80% in 2023, then soared by 478,613bps to 4,073.33% in 2024, then slumped by 633,723bps to -3,681.99% in 2025.
  • Its last three reported values are -3,681.99% in Q3 2025, 43,745.83% for Q2 2025, and 6,223.33% during Q1 2025.